Eli Lilly & Co (NYSE:LLY) Expects Higher Earnings in 2013; Backs FY 2012 Outlook – LLY, GSK, SNY, JNJ

Eli Lilly & Co (NYSE:LLY) maintained its earnings forecast for fiscal year 2012 on Friday regardless of the deferral of a projected tax benefit to the coming year. Eli Lilly estimates fiscal 2013 earnings to be over analysts’ forecasts even as it will lose patent protection for 2 key drugs in the year.

Drug maker also reaffirmed its commitment to fund dividends almost at the present level and done a $1.5 billion share buyback plan in 2013.

Indianapolis based Eli Lilly previously estimate fiscal year 2012 announced earnings in a range of $3.68 to $3.78 a share and adjusted earnings in the range of $3.30 to $3.40 a share.

Thomson Reuters analysts survey on average anticipated the company to earn $3.36 a share on $22.42 billion of revenues.

Shifting reader’s focus to broader market, let us consider market performance of other stocks that significantly affect same sector. GlaxoSmithKline plc (ADR) (NYSE:GSK) rose +0.64% to settle at $44.26, Sanofi SA (ADR) (NYSE:SNY) moved up +0.67% to end at $48.03 while Johnson & Johnson (NYSE:JNJ) jumped +1.15% to finish at $71.55 on Friday.

Eli Lilly & Co. (NYSE:LLY) last session’s volume of 13.59 million shares was surprisingly higher than its average volume of 6.67 million shares. The stock after opening at $51.06 hit high price of $51.90 and then closed at $51.56 by scoring +3.70%.

The liquidity measure in recent quarter results of the company was recorded 2.02 as current ratio and on the other side the debt to equity ratio was 0.34 and long-term debt to equity ratio remained at 0.34. The Company had total cash of $6.90 billion at hand and a book value per share as $14.35 in the most recent quarter.

The stock’s price volatility was 1.85% for a week and 1.68% for a month as well as price volatility’s Average True Range for 14 days was 0.92 and its beta remained at 0.69.

LLY generated revenue of $22.69 billion in the previous twelve months and earned $4.12 billion. The Company showed a positive 18.15% in the net profit margin as well as in its operating margin which remained at 23.96%. Company’s annual sales growth for the past five years was 9.13%.

DO NOT TRADE ANY STOCK WITHOUT LEVEL 2 STOCK QUOTES! QuoteDaddy.com delivers it's user with the most in-depth Level 2 Quotation System available on the Planet! NO Downloads, NO Widgets, NO Plugins required! Stay on TOP of your trades with QuoteDaddy.com! CLICK HERE TO START YOUR FREE 30-DAY TRIAL

This entry was posted in Healthcare, Latest Headlines and tagged , , , , , , , , , , , . Bookmark the permalink.